Viridian Therapeutics, Inc.

Greetings and welcome to the Viridian Therapeutics conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to John Jordan, Vice President of Investor Relations. Thank you. You may begin.

Thank you, Daryl. Good morning, everyone, and welcome to the Verdean conference call to discuss the initial clinical data for VRDN001 in patients with thyroid eye disease. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and 10-Q and other reports on file with the SEC. I would now like to turn the call over to Jonathan Violin, President and Chief Executive Officer of Viridian.

Thanks, John, and good morning, everyone. We're excited to share some remarkable data from our ongoing trial of VRDN001 for the treatment of thyroid eye disease, or TED. The results are, frankly, outstanding, and I'm pleased that we can now share our plans for accelerating VRDN001 as quickly as possible to Phase III with the aim of launching a new best-in-class intravenous therapy for thyroid eye disease. We'll also share today our first data for VRDN002, more excellent results. In this case, paving the way for us to develop a best-in-class, low-volume subcutaneous product just every two or four weeks to launch shortly after our IV product. We'll share our plans in a moment. I'm joined today by Dr. Barrett Katz, our Chief Medical Officer, Christian Humer, our Chief Financial Officer and Chief Business Officer, And most gratefully, Dr. Ray Douglas, Director of the Thyroid Eye Disease Program at Cedars-Sinai Hospital in Los Angeles, our lead PI in the U.S., an internationally recognized clinician scientist, and arguably the world's foremost authority on TED. Let's get started. We have much to share with you. I'll start with a brief overview of the findings and then hand it over to Barrett and Dr. Douglas to review the data for VRDN001 in more detail. after which I'll review some new mechanistic data that we think establishes VRDN001 as unique in its class and provide the clear scientific rationale supporting the impressive clinical efficacy data we're reporting today. I'll also review the initial findings from our VRDN002 program, demonstrating the extended half-life we set out to achieve. Then I'll provide an update on the acceleration of our TED strategy based on today's results, including our Phase III program for VRDN001, which we've named Thrive. which will be initiated before year end. I'll also share our plans to develop a best-in-class subcutaneous TED therapy, something we now have increased confidence in based on today's data. Next, Christian will review our second quarter financial results.